{"entity":{"edinet_code":"E35791","sec_code":"4886","name_ja":"あすか製薬ホールディングス株式会社","name_en":"ASKA Pharmaceutical Holdings Co., Ltd.","industry":"医薬品","industry_en":"Pharmaceutical"},"names_note":"English company names are as filed: each company's own annual report states its English name on the cover page. For a company that files no annual report, EDINET's filer registry is used instead. The as-filed Japanese name is always returned alongside.","filing":{"doc_id":"S100YEAY","filer_name":"あすか製薬ホールディングス株式会社","filer_name_en":"ASKA Pharmaceutical Holdings Co., Ltd.","period_end":"2026-03-31","filed_date":"2026-06-19","sha256":"0c2c8b46bce092295539afcb427ba3a6680a2ce006a40dab3ecc05e27ee51614","status":"clean"},"basis":{"measurement":"carrying_amount","entity_scope":"largest_holding_company","share_scope":"both","trust_included":"unknown","as_of":"2026-03-31","period_type":"annual","labels":{"measurement":"Balance-sheet carrying amount. Under Japanese GAAP listed equities are carried at market with the valuation difference in other comprehensive income, so carrying amount and acquisition cost diverge enormously on positions bought decades ago.","entity_scope":"The group's largest holder of policy shares (最大保有会社) — at a bank group this is the commercial bank, which excludes trust-bank and securities-subsidiary holdings.","share_scope":"Listed and unlisted shares together.","trust_included":"The filing does not state whether retirement-benefit-trust shares are included. Never guessed — shares contributed to such a trust leave the holder's balance sheet while the settlor normally keeps the right to instruct the vote.","period_type":"From an annual securities report (有価証券報告書). The policy shareholding table appears only in the annual report."},"not_comparable":"Figures are balance-sheet CARRYING AMOUNT at fiscal year end, from the annual securities report. They are NOT comparable with the acquisition-cost or book-value-reduction figures quoted in press coverage and IR presentations, and NOT comparable with interim (half-year) figures, which this product does not hold. Always state the basis with the number, and use check_claim before setting one of our figures against a published one."},"basis_note":"The basis every yen figure on this response is on. entity_scope is read from the filing's own disclosing entities, not assumed: scale_entities and flows each carry their own entity_scope and share_scope, and a figure quoted for one entity is not the group figure.","holdings":[{"holder_table":"largest","held_name_raw":"㈱三菱ＵＦＪフィナンシャル・グループ","held_name_en":"Mitsubishi UFJ Financial Group, Inc.","held_sec_code":"8306","match_status":"matched","shares":1193854,"book_value_yen":3104000000,"prior_shares":1193854,"prior_book_value_yen":2400000000,"purpose_ja":"取引金融機関を傘下に持つ金融持株会社であり、財務面において同社グループ企業との長期的な取引関係を維持・強化するため","reciprocal":"有","pct_outstanding":0.010568494934653361,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":4.040667022481418,"pct_of_holder_assets":2.762081883625944,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":["holding-company reorganisation"],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱大阪ソーダ","held_name_en":"OSAKA SODA CO., LTD.","held_sec_code":"4046","match_status":"matched","shares":1230000,"book_value_yen":2099000000,"prior_shares":1230000,"prior_book_value_yen":1997000000,"purpose_ja":"事業経営の観点から中長期的な関係維持と事業拡大を図るため","reciprocal":"有","pct_outstanding":1.0012040088696907,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":2.7323969330504174,"pct_of_holder_assets":1.8677866861246317,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"稲畑産業㈱","held_name_en":"Inabata & Co.,Ltd.","held_sec_code":"8098","match_status":"matched","shares":393300,"book_value_yen":1553000000,"prior_shares":393300,"prior_book_value_yen":1246000000,"purpose_ja":"事業経営の観点から中長期的な関係維持と事業拡大を図るため","reciprocal":"有","pct_outstanding":0.7332703201874353,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":2.0216352725237248,"pct_of_holder_assets":1.3819307877806353,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"ゼリア新薬工業㈱","held_name_en":"ZERIA PHARMACEUTICAL CO., LTD.","held_sec_code":"4559","match_status":"matched","shares":374000,"book_value_yen":820000000,"prior_shares":374000,"prior_book_value_yen":844000000,"purpose_ja":"事業経営の観点から中長期的な関係維持と事業拡大を図るため","reciprocal":"有","pct_outstanding":0.8484671669295629,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.067444252073055,"pct_of_holder_assets":0.729673693483658,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱めぶきフィナンシャルグループ","held_name_en":"Mebuki Financial Group,Inc.","held_sec_code":"7167","match_status":"matched","shares":620100,"book_value_yen":739000000,"prior_shares":620100,"prior_book_value_yen":450000000,"purpose_ja":"取引金融機関を傘下に持つ金融持株会社であり、財務面において同社グループ企業との長期的な取引関係を維持・強化するため","reciprocal":"有","pct_outstanding":0.0660698243419981,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.9620015881487652,"pct_of_holder_assets":0.6575961701029551,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":["holding-company reorganisation"],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱いよぎんホールディングス","held_name_en":"Iyogin Holdings, Inc.","held_sec_code":"5830","match_status":"matched","shares":194875,"book_value_yen":551000000,"prior_shares":194875,"prior_book_value_yen":342000000,"purpose_ja":"取引金融機関であり、財務面において同社との長期的な取引関係を維持・強化するため","reciprocal":"有","pct_outstanding":0.06727679693165745,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.7172704669417722,"pct_of_holder_assets":0.49030512818231164,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"戸田建設㈱","held_name_en":"TODA CORPORATION","held_sec_code":"1860","match_status":"matched","shares":282200,"book_value_yen":408000000,"prior_shares":282200,"prior_book_value_yen":248000000,"purpose_ja":"生産設備を主とする設備投資等にかかる取引先であり、同社との中長期的な取引関係を維持・強化するため","reciprocal":"有","pct_outstanding":0.09416871542019323,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5311186034704956,"pct_of_holder_assets":0.36305715480650297,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱東邦銀行","held_name_en":"The Toho Bank, Ltd.","held_sec_code":"8346","match_status":"matched","shares":600000,"book_value_yen":387000000,"prior_shares":600000,"prior_book_value_yen":213000000,"purpose_ja":"取引金融機関であり、財務面において同社との長期的な取引関係を維持・強化するため","reciprocal":"有","pct_outstanding":0.24010814470837666,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5037816165271612,"pct_of_holder_assets":0.34437038948558,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"武田薬品工業㈱","held_name_en":"Takeda Pharmaceutical Company Limited","held_sec_code":"4502","match_status":"matched","shares":50000,"book_value_yen":283000000,"prior_shares":50000,"prior_book_value_yen":220000000,"purpose_ja":"重要取引先であり、事業拡大や長期的な取引関係の維持・強化を図るため","reciprocal":"有","pct_outstanding":0.003154695724616096,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3683984430935055,"pct_of_holder_assets":0.2518264088486283,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"ダイキン工業㈱","held_name_en":"DAIKIN INDUSTRIES,LTD.","held_sec_code":"6367","match_status":"matched","shares":8800,"book_value_yen":164000000,"prior_shares":8800,"prior_book_value_yen":142000000,"purpose_ja":"生産設備を主とする設備投資等にかかる取引先であり、同社との中長期的な取引関係を維持するため","reciprocal":"有","pct_outstanding":0.0030050839908511173,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.21348885041461096,"pct_of_holder_assets":0.1459347386967316,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"有機合成薬品工業㈱","held_name_en":"YUKI GOSEI KOGYO CO., LTD.","held_sec_code":"4531","match_status":"matched","shares":366000,"book_value_yen":142000000,"prior_shares":366000,"prior_book_value_yen":96000000,"purpose_ja":"医薬品事業における取引先であり、同社との中長期的な取引関係を維持するため","reciprocal":"有","pct_outstanding":1.6933704085834447,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.18485010218826073,"pct_of_holder_assets":0.12635812740814564,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱バイタルケーエスケー・ホールディングス","held_name_en":"VITAL KSK HOLDINGS,INC.","held_sec_code":"3151","match_status":"matched","shares":93460,"book_value_yen":136000000,"prior_shares":93460,"prior_book_value_yen":117000000,"purpose_ja":"医薬品事業等における特約店であり、中長期的な取引関係の維持と強化を図るため","reciprocal":"有","pct_outstanding":0.19279215602855254,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.17703953449016518,"pct_of_holder_assets":0.12101905160216767,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"山九㈱","held_name_en":"SANKYU INC.","held_sec_code":"9065","match_status":"matched","shares":14674,"book_value_yen":128000000,"prior_shares":14674,"prior_book_value_yen":89000000,"purpose_ja":"事業経営の観点から中長期的な関係維持と事業拡大を図るため","reciprocal":"有","pct_outstanding":0.02927332433508768,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.16662544422603784,"pct_of_holder_assets":0.11390028386086369,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱スズケン","held_name_en":"SUZUKEN CO.,LTD.","held_sec_code":"9987","match_status":"matched","shares":21232,"book_value_yen":126000000,"prior_shares":21232,"prior_book_value_yen":104000000,"purpose_ja":"医薬品事業等における特約店であり、中長期的な取引関係の維持と強化を図るため","reciprocal":"有","pct_outstanding":0.031390682951973205,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.16402192166000598,"pct_of_holder_assets":0.1121205919255377,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱ほくやく・竹山ホールディングス","held_name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","held_sec_code":"3055","match_status":"matched","shares":112500,"book_value_yen":103000000,"prior_shares":112500,"prior_book_value_yen":99000000,"purpose_ja":"医薬品事業等における特約店であり、中長期的な取引関係の維持と強化を図るため","reciprocal":"有","pct_outstanding":0.5472801393253617,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.13408141215063982,"pct_of_holder_assets":0.09165413466928875,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"ダイト㈱","held_name_en":"Daito Pharmaceutical Co.,Ltd.","held_sec_code":"4577","match_status":"matched","shares":48400,"book_value_yen":69000000,"prior_shares":24200,"prior_book_value_yen":52000000,"purpose_ja":"医薬品事業における取引先であり、同社との中長期的な取引関係を維持するため。なお、株式数が増加した理由は、同社が2025年６月１日付で１株につき２株の割合で実施した株式分割によるものであります。","reciprocal":"有","pct_outstanding":0.16783306020005423,"pct_unavailable":null,"pct_basis_period_end":"2026-05-31","pct_share_classes":1,"pct_of_holder_equity":0.08982152852809852,"pct_of_holder_assets":0.06139937176874683,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":["share split"],"note_refs":[],"share_ratio":2.0,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱シーボン","held_name_en":"Ｃ'ＢＯＮ ＣＯＳＭＥＴＩＣＳ Ｃｏ.,Ｌｔｄ.","held_sec_code":"4926","match_status":"matched","shares":17300,"book_value_yen":21000000,"prior_shares":17300,"prior_book_value_yen":19000000,"purpose_ja":"その他の事業において取引があり、中長期的な関係の維持と強化を図るため","reciprocal":"有","pct_outstanding":0.41580541268086335,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.02733698694333433,"pct_of_holder_assets":0.01868676532092295,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱メディパルホールディングス","held_name_en":"MEDIPAL HOLDINGS CORPORATION","held_sec_code":"7459","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":136911,"prior_book_value_yen":319000000,"purpose_ja":"医薬品事業等における特約店であり、中長期的な取引関係の維持と強化を図るため保有しておりましたが、当事業年度に売却しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"三菱ＨＣキャピタル㈱","held_name_en":"Mitsubishi HC Capital Inc.","held_sec_code":"8593","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":500000,"prior_book_value_yen":503000000,"purpose_ja":"リース取引にかかる取引先であり、同社との中長期的な取引関係を維持するため保有しておりましたが、当事業年度に売却しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"加賀電子㈱","held_name_en":"KAGA ELECTRONICS CO.,LTD.","held_sec_code":"8154","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":142000,"prior_book_value_yen":383000000,"purpose_ja":"事業経営の観点から中長期的な関係維持と事業拡大を図るため保有しておりましたが、当事業年度に売却しております。","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱ＣＡＣ　Ｈｏｌｄｉｎｇｓ","held_name_en":"CAC Holdings Corporation","held_sec_code":"4725","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":200900,"prior_book_value_yen":416000000,"purpose_ja":"事業経営の観点から中長期的な関係維持と事業拡大を図るため保有しておりましたが、当事業年度に売却しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false}],"holders":[{"holder_name":"武田薬品工業株式会社","holder_name_en":"Takeda Pharmaceutical Company Limited","holder_sec_code":"4502","doc_id":"S100YB5L","period_end":"2026-03-31","holder_table":"reporting","shares":2204840,"book_value_yen":5203000000,"prior_shares":2204840,"prior_book_value_yen":5080000000,"purpose_ja":"（保有目的）当社事業における取引関係および提携関係の維持のための投資（業務提携等の概要）医薬品の流通および製品導出に関する業務提携（定量的な保有効果）（注）１","reciprocal":"有（注）２","pct_outstanding":7.764013485503077,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.07002080168232949,"pct_of_holder_assets":0.03354284232620611,"holder_equity_basis":"ifrs_consolidated","holder_equity_yen":7430649000000,"holder_total_assets_yen":15511506000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ゼリア新薬工業株式会社","holder_name_en":"ZERIA PHARMACEUTICAL CO., LTD.","holder_sec_code":"4559","doc_id":"S100YKC2","period_end":"2026-03-31","holder_table":"reporting","shares":1877900,"book_value_yen":4431844000,"prior_shares":1877900,"prior_book_value_yen":4326681000,"purpose_ja":"（保有目的）医療用医薬品事業及びコンシューマーヘルスケア事業活動の円滑な推進（定量的な保有効果）（注）１","reciprocal":"無（注）２","pct_outstanding":6.612743294037767,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":4.080707674127448,"pct_of_holder_assets":2.466274114235995,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":108604790000,"holder_total_assets_yen":179697949000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社大阪ソーダ","holder_name_en":"OSAKA SODA CO., LTD.","holder_sec_code":"4046","doc_id":"S100YKCT","period_end":"2026-03-31","holder_table":"reporting","shares":364000,"book_value_yen":859000000,"prior_shares":364000,"prior_book_value_yen":838000000,"purpose_ja":"（保有目的）医薬関連事業における取引先であり、同社との関係を維持・強化することにより、当社グループの持続的な成長と中長期的な企業価値の維持・向上に資すると認められるためです。","reciprocal":"有","pct_outstanding":1.2817714250118466,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.668269268171245,"pct_of_holder_assets":0.5090641871270172,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":128541000000,"holder_total_assets_yen":168741000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社めぶきフィナンシャルグループ","holder_name_en":"Mebuki Financial Group,Inc.","holder_sec_code":"7167","doc_id":"S100YAVM","period_end":"2026-03-31","holder_table":"largest","shares":300000,"book_value_yen":708000000,"prior_shares":300000,"prior_book_value_yen":691000000,"purpose_ja":"（保有目的）地域経済の成長・活性化において、先進的な知見や技術等の活用が期待できる中央有力企業との関係維持・強化等を通じた当社グループの企業価値向上を目的に保有しております。（定量的な保有効果）上記②aイに記載の検証方法に従って検証した結果、収益性、信用力、地域性（当社の主要営業地盤との関係等）、取引関係強化等を加味し、総合的な判断による合理性が認められるため保有しております。","reciprocal":"無","pct_outstanding":1.0564050206141593,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.06572644431076353,"pct_of_holder_assets":0.003343788813099491,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":1077192000000,"holder_total_assets_yen":21173586000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社東邦銀行","holder_name_en":"The Toho Bank, Ltd.","holder_sec_code":"8346","doc_id":"S100Y9W6","period_end":"2026-03-31","holder_table":"reporting","shares":290000,"book_value_yen":684000000,"prior_shares":290000,"prior_book_value_yen":668000000,"purpose_ja":"いわき市に生産拠点を有しており、総合的な銀行取引の維持・強化によって、当行の安定的・長期的な企業価値向上を図る為に保有。","reciprocal":"無 （注３）","pct_outstanding":1.0211915199270207,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3141260269946314,"pct_of_holder_assets":0.0101447811552681,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":217747000000,"holder_total_assets_yen":6742383000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社いよぎんホールディングス","holder_name_en":"Iyogin Holdings, Inc.","holder_sec_code":"5830","doc_id":"S100YBIB","period_end":"2026-03-31","holder_table":"largest","shares":290000,"book_value_yen":684000000,"prior_shares":290000,"prior_book_value_yen":668000000,"purpose_ja":"業界内での有力企業であり、総合的な関係の維持強化を図ることにより当社グループの中長期的な企業価値の向上に資するため保有しております。","reciprocal":"無(注４)","pct_outstanding":1.0211915199270207,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.07791479948330185,"pct_of_holder_assets":0.007169952615418417,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":877882000000,"holder_total_assets_yen":9539812000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"稲畑産業株式会社","holder_name_en":"Inabata & Co.,Ltd.","holder_sec_code":"8098","doc_id":"S100YB2W","period_end":"2026-03-31","holder_table":"reporting","shares":236500,"book_value_yen":558000000,"prior_shares":236500,"prior_book_value_yen":544000000,"purpose_ja":"保有目的：その他事業において同社との取引関係・協業関係の構築・維持強化のため。定量的な保有効果：記載は困難である。保有の合理性を検証した方法：上記（５）②ａ．参照のこと。","reciprocal":"有","pct_outstanding":0.832799291250829,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2268864510567704,"pct_of_holder_assets":0.1120171518735772,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":245938000000,"holder_total_assets_yen":498138000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"戸田建設株式会社","holder_name_en":"TODA CORPORATION","holder_sec_code":"1860","doc_id":"S100YG3E","period_end":"2026-03-31","holder_table":"reporting","shares":194100,"book_value_yen":458000000,"prior_shares":194100,"prior_book_value_yen":447000000,"purpose_ja":"主要取引先であり、保有により取引関係が強化され、主に建築セグメントにおける中長期的な工場等の工事受注量の確保等に資するため、保有継続が適当と判断しております。","reciprocal":"無（注３）","pct_outstanding":0.6834940483373612,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.11360225815493066,"pct_of_holder_assets":0.045873443382855955,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":403161000000,"holder_total_assets_yen":998399000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社伊予銀行","holder_name_en":"The Iyo Bank, Ltd.","holder_sec_code":"8385","doc_id":"S100OLYJ","period_end":"2022-03-31","holder_table":"reporting","shares":290000,"book_value_yen":366000000,"prior_shares":null,"prior_book_value_yen":null,"purpose_ja":"緊密な関係の維持強化、持株会社体制への移行に伴う株式交換により株式数が増加","reciprocal":"無(注４)","pct_outstanding":1.0268431311931254,"pct_unavailable":null,"pct_basis_period_end":"2022-03-31","pct_share_classes":1,"pct_of_holder_equity":0.05001380162285221,"pct_of_holder_assets":0.0042833083103086,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":731798000000,"holder_total_assets_yen":8544797000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"有機合成薬品工業株式会社","holder_name_en":"YUKI GOSEI KOGYO CO., LTD.","holder_sec_code":"4531","doc_id":"S100YHPD","period_end":"2026-03-31","holder_table":"reporting","shares":150000,"book_value_yen":354000000,"prior_shares":150000,"prior_book_value_yen":345000000,"purpose_ja":"医薬品関係で取引があり、同社との関係強化のため、同社株式を保有しております。","reciprocal":"有","pct_outstanding":0.5282025103070797,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":2.6247497590272113,"pct_of_holder_assets":1.375825884181889,"holder_equity_basis":"parent_only","holder_equity_yen":13487000000,"holder_total_assets_yen":25730000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社ＣＡＣ　Ｈｏｌｄｉｎｇｓ","holder_name_en":"CAC Holdings Corporation","holder_sec_code":"4725","doc_id":"S100XSXA","period_end":"2025-12-31","holder_table":"reporting","shares":160500,"book_value_yen":327000000,"prior_shares":160500,"prior_book_value_yen":336000000,"purpose_ja":"安定的な取引関係の維持・強化を目的として保有しております。","reciprocal":"有","pct_outstanding":0.5651766860285753,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.9131017536021445,"pct_of_holder_assets":0.6087231705727955,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":35812000000,"holder_total_assets_yen":53719000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"山九株式会社","holder_name_en":"SANKYU INC.","holder_sec_code":"9065","doc_id":"S100YJRS","period_end":"2026-03-31","holder_table":"reporting","shares":66550,"book_value_yen":157000000,"prior_shares":66550,"prior_book_value_yen":153000000,"purpose_ja":"当社事業展開への影響等を勘案し、同社株式を継続して保有しております。","reciprocal":"無(注9)","pct_outstanding":0.23434584707290768,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.05114206418491928,"pct_of_holder_assets":0.028048436255015668,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":306988000000,"holder_total_assets_yen":559746000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"ダイキン工業株式会社","holder_name_en":"DAIKIN INDUSTRIES,LTD.","holder_sec_code":"6367","doc_id":"S100YFQL","period_end":"2026-03-31","holder_table":"reporting","shares":60000,"book_value_yen":141000000,"prior_shares":60000,"prior_book_value_yen":138000000,"purpose_ja":"同社グループは当社の空調事業における販売先であり、相互の事業拡大や取引関係の強化を目的に株式を保有しております。","reciprocal":"無（注15）","pct_outstanding":0.21128100412283188,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.004251421210913308,"pct_of_holder_assets":0.0024271677534410696,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":3316538000000,"holder_total_assets_yen":5809240000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社バイタルケーエスケー・ホールディングス","holder_name_en":"VITAL KSK HOLDINGS,INC.","holder_sec_code":"3151","doc_id":"S100YDSN","period_end":"2026-03-31","holder_table":"second_largest","shares":46000,"book_value_yen":108000000,"prior_shares":46000,"prior_book_value_yen":105000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無(注５)","pct_outstanding":0.16198210316083778,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.09098031287118705,"pct_of_holder_assets":0.03369019989518605,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"ダイト株式会社","holder_name_en":"Daito Pharmaceutical Co.,Ltd.","holder_sec_code":"4577","doc_id":"S100YYNI","period_end":"2026-05-31","holder_table":"reporting","shares":20000,"book_value_yen":58000000,"prior_shares":20000,"prior_book_value_yen":46000000,"purpose_ja":"(保有目的) 当社の原薬及び製剤の販売先であり、取引関係の維持・強化を目的として保有しております。","reciprocal":"無(注３)","pct_outstanding":0.07042700137427729,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.10956212928331255,"pct_of_holder_assets":0.07913659248748141,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":52938000000,"holder_total_assets_yen":73291000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社スズケン","holder_name_en":"SUZUKEN CO.,LTD.","holder_sec_code":"9987","doc_id":"S100YFRU","period_end":"2026-03-31","holder_table":"reporting","shares":21000,"book_value_yen":49000000,"prior_shares":21000,"prior_book_value_yen":48000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"無(注)２","pct_outstanding":0.07394835144299115,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.011778506389238773,"pct_of_holder_assets":0.004239612516720513,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社バイタルケーエスケー・ホールディングス","holder_name_en":"VITAL KSK HOLDINGS,INC.","holder_sec_code":"3151","doc_id":"S100YDSN","period_end":"2026-03-31","holder_table":"largest","shares":2662,"book_value_yen":6000000,"prior_shares":2662,"prior_book_value_yen":6000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無(注４)","pct_outstanding":0.009373833882916308,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.005054461826177058,"pct_of_holder_assets":0.0018716777719547802,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false}],"reclassified":[],"reclassified_note":"As filed, from the annual report's 保有目的を変更した投資株式 table. direction=to_pure means the filer moved the holding from a policy shareholding to 純投資目的 (pure investment); the shares are not necessarily sold, and the position leaves the named policy table in the year of the change. direction=to_policy is the reverse. fy_of_change_ja is the fiscal year the filer states the change took effect, verbatim — some filers list more than one. A filing repeats these rows for several years after the change, so this is a standing disclosure, not a one-year event.","implausible_note":"A row is flagged implausible when its two filed numbers are mutually impossible — book value ÷ shares of ¥1,000,000 or more, which no listed Japanese share reaches. It is a filer tagging error (a value entered at the wrong scale, or a share count in thousands), not an extraction error: the values match the filing's XBRL exactly. Flagged rows are still returned, exactly as filed, but are excluded from the yen aggregates here and counted in excluded_positions / excluded_yen so the exclusion is visible.","notes":[{"holder_table":"largest","note_no":"1","text_ja":"（注）「－」は、当該銘柄を保有していないことを示しております。"}],"notes_note":"The filing's own numbered footnotes to the named policy table, verbatim. The XBRL numbers them (注)1, (注)2 … and gives no link back to a row, so a note is tied to a position only where it names that issuer.","flows":[{"holder_table":"largest","share_class":"listed","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":4,"sale_proceeds_yen":2074000000,"entity_scope":"largest_holding_company","share_scope":"listed"},{"holder_table":"largest","share_class":"unlisted","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":null,"sale_proceeds_yen":null,"entity_scope":"largest_holding_company","share_scope":"unlisted"}],"flows_note":"The filer's own tally, as filed, of how many issues increased or decreased during the year and the yen involved — acquisition cost for increases, sale proceeds for decreases. Read against the reclassification table this separates what was actually sold from what merely changed category. Counts are as filed and are not corrected for filer tagging errors.","no_reduction_measure":"This product holds sale proceeds (売却価額), as filed, for one fiscal year. It does NOT hold a book-value-reduction measure. The two are different measures and must never be presented as equivalent.","scale":{"policy_total_yen":11246000000,"listed_yen":10842000000,"unlisted_yen":404000000,"listed_issues":17,"unlisted_issues":7,"equity_yen":76819000000,"equity_basis":"jgaap_consolidated","total_assets_yen":112379000000,"assets_basis":"jgaap_consolidated","pct_of_equity":14.639607388797042,"pct_of_assets":10.00720775233807,"equity_basis_label":"Consolidated net assets (Japanese GAAP)","assets_basis_label":"Consolidated net assets (Japanese GAAP)","equity_calc":"total policy shareholdings ÷ shareholders' equity × 100, both as filed in this annual securities report","assets_calc":"total policy shareholdings ÷ total assets × 100, both as filed in this annual securities report"},"scale_entities":[{"holder_table":"largest","share_class":"listed","book_value_yen":10842000000,"issue_count":17,"holder_table_label":"Largest holder in the group","entity_scope":"largest_holding_company","share_scope":"listed"},{"holder_table":"largest","share_class":"unlisted","book_value_yen":404000000,"issue_count":7,"holder_table_label":"Largest holder in the group","entity_scope":"largest_holding_company","share_scope":"unlisted"}],"scale_history":[{"year":"2022","period_end":"2022-03-31","policy_total_yen":9359000000,"equity_yen":48892000000,"equity_basis":"jgaap_consolidated","pct_of_equity":19.142190951484906,"pct_of_assets":11.235698764661393},{"year":"2023","period_end":"2023-03-31","policy_total_yen":11252000000,"equity_yen":54533000000,"equity_basis":"jgaap_consolidated","pct_of_equity":20.633377954632973,"pct_of_assets":12.912850880212995},{"year":"2024","period_end":"2024-03-31","policy_total_yen":10958000000,"equity_yen":61930000000,"equity_basis":"jgaap_consolidated","pct_of_equity":17.69417083804295,"pct_of_assets":12.075596451595128},{"year":"2025","period_end":"2025-03-31","policy_total_yen":11015000000,"equity_yen":69195000000,"equity_basis":"jgaap_consolidated","pct_of_equity":15.918780258689212,"pct_of_assets":10.956492330952713},{"year":"2026","period_end":"2026-03-31","policy_total_yen":11246000000,"equity_yen":76819000000,"equity_basis":"jgaap_consolidated","pct_of_equity":14.639607388797042,"pct_of_assets":10.00720775233807}],"scale_note":"The policy total is Official (as filed) — the filing's own total carrying amount for the whole policy bucket, listed and unlisted, summed across the entities the filing discloses. It is a floor: holdings at group companies the filing does not name are disclosed nowhere and are not included. The percentages are calculated, not filed, and carry their formula. equity_basis names which figure the denominator is, because filers report under Japanese, IFRS or US accounting standards and an adopter of the latter two stops tagging the Japanese consolidated figure — a parent-only denominator is a different measure and is labelled as one, never silently mixed with a group figure. Percentages are null where equity or total assets is missing or not positive; missing is never shown as zero.","scale_reference":"ISS's Japan proxy voting guidelines recommend a vote against the top executive at a company that allocates 20 percent or more of its net assets to cross-shareholdings, a policy effective from February 2022. ISS counts unilateral holdings, not only mutual ones.","ownership_calc":"shares held ÷ (issuer's issued shares − treasury shares) × 100, both as filed, the denominator taken from the issuer's own annual securities report nearest the holding's fiscal year end","ownership_note":"Derived, not filed. The denominator is the issuer's own reported issued shares less treasury shares, from its annual report nearest this holding's fiscal year end on either side — pct_basis_period_end gives that date, and it can fall after the holding's date where that report is the closer one. For a single-class listed stock this equals the stake's share of market capitalisation. It is null where the issuer files no annual report we hold; where the issuer's share count moves by half or more across the window, because a split or issue makes the share base indeterminate; and where the result would exceed 100%, which is a data fault rather than a stake. It is less exact where the issuer has more than one share class (pct_share_classes > 1), because treasury shares are reported across all classes.","holder_share_calc":"this position's book value ÷ the holder's shareholders' equity (or total assets) × 100, both as filed in the holder's own annual securities report","holder_share_note":"The mirror of pct_outstanding. That sizes a stake against the ISSUER — how much of the issuer this holder owns. pct_of_holder_equity and pct_of_holder_assets size the same position against the HOLDER: how much of its own capital is committed to this one name. Calculated, not filed. Null where the holder's filing gives no usable denominator, never zero. holder_equity_basis says which accounting figure the denominator is, and a parent_only basis is not comparable with a consolidated one. A position CAN legitimately exceed 100% of equity — a holder whose book equity is smaller than one long-held stake is a real and commercially interesting case, not an error — so no ceiling is imposed. Extreme values are worth checking against the filing: where the position's own two filed numbers are mutually impossible the row is marked `implausible`, but that test catches only scale errors visible per share, so it does not catch every bad figure. The book value and share count are returned alongside so the reader can check.","action_calc":"keyword match over the filing's own stated purpose and table footnotes: 株式分割、株式併合、株式交換、株式移転、会社分割、合併、持株会社、商号変更、公開買付、上場廃止","ratio_calc":"current shares ÷ prior shares where that ratio is an exact whole number (or its exact reciprocal) — the signature of a split or a consolidation rather than a trade","history":[{"year":"2022","period_end":"2022-03-31","named_holdings":32,"book_value_yen":8993000000},{"year":"2023","period_end":"2023-03-31","named_holdings":31,"book_value_yen":10888000000},{"year":"2024","period_end":"2024-03-31","named_holdings":28,"book_value_yen":10244000000},{"year":"2025","period_end":"2025-03-31","named_holdings":23,"book_value_yen":10299000000},{"year":"2026","period_end":"2026-03-31","named_holdings":21,"book_value_yen":10833000000}],"history_note":"One point per annual report filed. Each year's book value is as filed; book values are fair-valued at period end, so a change reflects both trading and market moves.","provenance":{"trust":"official","note":"Figures exactly as filed in each company's 有価証券報告書 (annual securities report), EDINET. Raw filings archived with SHA-256; doc_id links to the source filing."}}